PLRX (pliantrx.com) Forward P/S Multiple

Pliant Therapeutics (PLRX) develops small molecules to combat lung and liver fibrosis, relying on insurance reimbursements. The innovative pipeline of integrin inhibitors is currently at its peak activity. The forward P/S history shows that the current status equals 3012.70, helping to assess market expectations. However, the absence of commercial products and the cost of trials preclude a stable cash flow.

Pliant Therapeutics Inc - PLRX Forward P/S Multiple (period 07/04/2022 - 08/08/2024)

Summary analytical data breakdowns for pliantrx.com (PLRX)

- market price and analyst price targets:

Price Chart Pliant Therapeutics, Inc.|PLRX - Forecast Levels Chart

- business market valuation indicators:

Market Capitalization PLRX|PLRX - Value Adjusted for Debt and Cash

- issuer book value statistics:

Book Value per Share Pliant Therapeutics|PLRX - Book Capitalization|Market Value to Book Value Ratio pliantrx.com|PLRX - Aggregate Asset Value

- debt and solvency information:

- financial results and valuation multiples details:

PLRX - Net Financial Result|Projected Future Earnings Pliant Therapeutics|PLRX - P/E Multiple|Future Price to Earnings Pliant Therapeutics, Inc.|PLRX - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio PLRX|PLRX - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months Pliant Therapeutics|PLRX - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months pliantrx.com|PLRX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Pliant Therapeutics

- total revenue and sales volume data:

PLRX - Company Sales Revenue|Projected Sales Volume Pliant Therapeutics, Inc.|PLRX - Price to Sales|Price-to-Projected Revenue Ratio PLRX

Fundamental company analysis:PLRX (Pliant Rx)

For Pliant Therapeutics (PLRX), which is developing an innovative therapy platform for fibrotic lung and liver diseases, the forward P/S metric allows for a correlation between market capitalization and expected revenue. The current value of 3012.70 reflects the ratio of share prices to updated management guidance, where a significant gap between valuation and actual earnings signals elevated risks of a deep capital correction.

Direct competitors

Price-to-Projected Revenue Ratio Vertex VRTX|ALNY (Alnylam Pharmaceuticals, Inc.) - Future Price to Revenue|Insmed Inc - Forward P/S Multiple|Forward Price to Sales UTHR (United Therapeutics Inc.)|BMRN: Forward P/S Multiple|bridgebio.com (BBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio BGM Group Limited|COGT: Forward Price to Sales|Price-to-Projected Revenue Ratio Xeris Biopharma Inc (XERS)|Forward Price-to-Revenue Multiple Keros Corp KROS|Forward P/S Multiple ARCT (Arcturus Therapeutics)|Forward P/S Multiple etonpharma.com ETON|KMDA - Price-to-Projected Revenue Ratio|Future Price to Revenue FULC|abeonatherapeutics.com (ABEO) - Price-to-Projected Revenue Ratio|MREO (Mereo BioPharma Group plc) - Price-to-Projected Revenue Ratio|PLX (Protalix BioTherapeutics) - Forward P/S Multiple|appliedtherapeutics.com (APLT) - Market Cap to Expected Sales Ratio|Forward P/S Multiple RNTX|Forward P/S Multiple gelteq.com (GELS)|Price-to-Projected Revenue Ratio Aytu BioPharma AYTU|CMMB: Market Cap to Projected Revenue|SRXH: Forward Price-to-Revenue Multiple|Polyrizon Ltd - Price to Expected Revenue Ratio|AEZS (zentaris.com) - Forward Price-to-Revenue Multiple|Cyclo Therapeutics Inc. - Forward Price to Sales|Forward Price-to-Revenue Multiple INZY|RPHM (Reneo Pharmaceuticals, Inc) - Price to Expected Revenue Ratio|Forward P/S Multiple CSCI